Skip to main content
NCBI home page
Molecular Medicine Reports logoLink to Molecular Medicine Reports
. 2017 Mar 16;15(5):2415–2422. doi: 10.3892/mmr.2017.6331

Matrine reduces the proliferation of A549 cells via the p53/p21/PCNA/eIF4E signaling pathway

Zhiyan Lu 1, Youzhang Xiao 2, Xing Liu 2,3, Zaipeng Zhang 1, Feng Xiao 2,✉, Yongyi Bi 3,✉
PMCID: PMC5428535  PMID: 28447756

Abstract

The aim of the present study was to investigate how matrine affects the proliferation of A549 human lung adenocarcinoma cells via the p53/p21/proliferating cell nuclear antigen (PCNA)/eukaryotic translation initiation factor 4E (eIF4E) signaling pathway. The effect of different concentrations of matrine on the proliferation of A549 cells was investigated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The migration of A549 cells following exposure to varied concentrations of matrine was detected using a Transwell cell migration assay. The effect of 240 mg/l matrine on the apoptotic rate of A549 cells was determined using flow cytometry. The change in the mRNA and protein expression levels of p53, p21, PCNA and eIF4E following exposure to matrine were detected using reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. The increase of matrine from 60–240 mg/l led to reduced cell migration and inhibition of A549 cell proliferation. The apoptotic rate of A549 cells when treated with 240 mg/l matrine was significantly different when compared with the untreated control. The mRNA expression levels of p53 and p21 in the group treated with 240 mg/l matrine were significantly higher compared with the control group. The mRNA expression levels of PCNA and eIF4E were significantly lower in the 240 mg/l matrine-treated group compared with the control. The protein expression levels of p53 and p21 were significantly higher in the 240 mg/l matrine group compared with the control group. Treatment with 240 mg/l matrine reduced the protein expression levels of PCNA and eIF4E. Matrine also reduced the migration ability of A549 cells and inhibited their proliferation, which may be associated with the overexpression of p53 and p21, and the reduction of PCNA and eIF4E expression levels.

Keywords: matrine, cells proliferation, p53, p21, proliferating cell nuclear antigen, eukaryotic translation initiation factor 4E, A549 cells

Introduction

Lung cancer is one of the frequent clinical malignancies (1). Chemotherapy has been adopted as the primary treatment method. However, the majority of lung cancer patients have not been sufficiently sensitive to traditional chemotherapy treatment (2). Matrine (C15H24N2O) is an alkaloid (3), which may inhibit the proliferation of A549 human lung adenocarcinoma cells (4) and non-small-cell lung cancer cells (5).

p53 is a well-known tumor suppressor gene (6), and in numerous types of cancer patients often have a dysfunctional p53 (7). p21 is an important member of the Cip family (8) and the cyclin-dependent kinase inhibitor family (9). A mutation in the p21 gene is associated with pancreatic cancer (10) and the differentiation of other malignant tumor types, including to the depth of invasion, proliferation and metastasis. Additionally, p21 has prognostic value; p21 expression has been documented as a poor prognostic marker in human lung cancer (11). Proliferating cell nuclear antigen (PCNA) is a protein expressed in proliferative stage cells or tumor cells (12). PCNA expression levels have been observed to change periodically throughout the cell cycle (13). The detection of PCNA expression in cells may be used as an indicator of the proliferation status of pancreatic cancer cells (14). Eukaryotic initiation factor 4E (eIF4E) is a cytokine associated with pancreatic cancer (15) and other malignant tumor types, which is important in the initiation of protein synthesis (16) and is closely associated with tumorigenesis, invasion and metastasis.

Therefore, the present study investigated if matrine is capable of reducing the proliferation of A549 lung cancer cells via the p53/p21/PCNA/eIF4E signaling pathway.

Materials and methods

Cell culture

Human lung adenocarcinoma A549 cells, were obtained from the Chinese Academy of Medical Sciences Tumor Cell Bank (Beijing, China). These cells were maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and incubated at 37°C in a 5% CO2 atmosphere.

Cell toxicity and proliferation assays

Adherent A549 cells were cultured by digestion. The cells were seeded at a density of 1.0×105 cells/well into 96-well plates. A control group and four groups of cells treated with different concentrations (60, 120, 180 and 240 mg/l) of matrine (National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China) were used. The control group was exposed to identical quantities of medium. The drug was diluted with distilled water and served as a vehicle control. Every 48 h, the medium was replaced with fresh medium containing the specified concentration of the drug. The cell groups were cultured for 6 days. A total of 20 µl (5 mg/ml) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China) were added to each well, and the samples were incubated for 4 h at 37°C. Following incubation, the absorbance (A) values of the microplate wells were determined at 570 nm. Cell proliferation inhibition rate = (l - Atreatment group / Acontrol group) × 100.

Transwell assay

Cells were seeded at 4×105/ml in two 6-well plates and treated with 1 ml 10% FBS, 1% penicillin/streptomycin and RPMI-1640. After 24 h, varying concentrations (60, 120, 180 and 240 mg/l) of matrine were administered to the different groups and the cells were maintained at 37°C for 48 h. The top of the transwell chamber contained 150 µl suspension (1×106 cell/ml), and the bottom contained 600 µl 10% FBS. The cells were gently removed from the top chamber with a cotton swab prior to staining with crystal violet. A total of three visual fields were randomly selected and images were captured using a fluorescence microscope (BX53; Olympus Corporation, Tokyo, Japan). Migrating cells were counted and statistical analysis was performed on the data obtained. The inhibition of cell migration inhibition = (1 - number of migrated cells in the intervention group / number of migrating cells in the control group) × 100.

Flow cytometry

The A549 cell suspension (3×104/ml) was placed at 2 ml per well into a 6-well plate and incubated for 12 h at 37°C in a an atmosphere of 5% CO2. After 12 h, the media was aspirated and the matrine was added at the aforementioned concentrations. Media with no cell suspension served as a blank control. Each treatment was performed in triplicate. The cells were trypsinized and collected, washed with cold phosphate-buffered saline (PBS) twice and 100 μl 1X annexin-binding buffer (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) was added. Annexin V (5 µl) was added, followed by 100 μg/ml propidium iodide (1 µl). Following a 15-min incubation in the dark at room temperature, 400 µl 1X annexin-binding buffer was added. Flow cytometry was performed using a BD FACSVerse™, BD Biosciences, Franklin Lakes, NJ, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Following treatment, the A549 cells were collected from the control group and the group treated with 240 mg/l matrine. The total RNA was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc.) and was reverse transcribed to obtain cDNA. β-actin was used as an internal reference. The qPCR primers (β-actin, p53, p21, PCNA and eIF4E) were synthesized by the Shanghai Biological Engineering Technology Services Limited (Table I). The CFX Connect Real-Time PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and the CFX Manager (Bio-Rad Laboratories, Inc.) were used for analysis according to the manufacturer's instructions. Each reaction contained 500 ng cDNA, 10 µl of 2X master mix, 0.5 µl primers and water for a final volume of 30 µl. A SuperReal Premix Plus (SYBR Green) from Tiangen Biotech Co., Ltd. (Beijing, China) was used. The threshold cycle value, that represents the cycle number at which sample fluorescence rises to a statistically significant level above the background, was calculated. CFX Manager uses the comparative Cq method for relative quantitative analysis, and the gene expression levels are presented as a fold change (17). All amplifications were run in triplicate and the mean value was applied for all calculations.

Table I.

Primer sequences for polymerase chain reaction.

Gene Forward (5′-3′) Reverse (5′-3′) Length (bp)
β-actin CCCATCTATGAGGGTTACGC TTTAATGTCACGCACGATTTC 150
p53 ACCTATGGAAACTACTTCCTGAAA CTGGCATTCTGGGAGCTTCA 141
p21 AGTCAGTTCCTTGTGGAGCC CATTAGCGCATCACAGTCGC 184
PCNA CAGAGCTCTTCCCTTACGCA GTCCTTGAGTGCCTCCAACA 200
eIF4E TTCCTTCTGACTGGGGGACT CCTCCTCTGTAGTCGGGGGA 192
Open in a new tab

PCNA, proliferating cell nuclear antigen; eIF4E, eukaryotic translation initiation factor 4E.

Western blotting

The cells were cultured for 24 h in 6-well plates at a density of 1.0×106 cells/cm2. Following incubation, the cells were collected and washed three times with ice-cold PBS. The cells were subsequently centrifuged for 5 min at 300 × g, and the supernatant was discarded. The total protein was extracted using RIPA (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Protein concentration was determined using the bicinchoninic acid assay method (Enhanced BCA Protein assay kit; Beyotime Institute of Biotechnology, Shanghai, China). Aliquots of 150 µg total protein were separated by 8% polyacrylamide gel electrophoresis. Tris-buffered saline/Tween-20 solution containing 1% bovine serum albumin (Sangon Biotech Co., Ltd., Shanghai, China) and non-fat milk was used to block the membranes overnight at 4°C. Following blocking, the membranes were incubated with the following primary antibodies at a dilution of 1:1,000: Polyclonal rabbit anti-p53 (cat. no. sc-6243), polyclonal rabbit anti-PCNA (cat. no. sc-7907), monoclonal mouse anti-p21 (cat. no. sc-271532) and monoclonal mouse anti-eIF4E (cat. no. sc-271480; Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA). The β-actin antibody (cat. no. sc-47778; dilution, 1:2,000 from Santa Cruz Biotechnology, Inc.) served as the loading control. The proteins were visualized using the following secondary antibodies: Goat anti-rabbit (1:4,000; cat. no. bs-0295G) and goat anti-mouse (1:4,000; cat. no. bs-0368Gs) antibody, purchased from Beijing Biosynthesis Biotechnology Co., Ltd. (Beijing, China). The bands were developed using an ECL system according to the manufacturer's protocols. ImageJ 1.48 software (National Institutes of Health, Bethesda, MD, USA) was used to determine the density of the bands in all blots.

Statistical analysis

When comparing two groups of data a paired samples t-test was performed. When comparing multiple groups a one-way analysis of variance followed by a post-hoc Tukey's test was used. Statistical analyses were conducted using SPSS version 22.0 (IBM SPSS, Armonk, NY, USA) and data are presented as means ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

Inhibitory action of matrine on A549 cell proliferation

A549 cells were treated with different concentrations of matrine (0, 60, 120, 180 and 240 mg/l) for 6 days. The A570 values in each group were measured using an MTT assay and the obtained data were utilized to produce a growth curve (Fig. 1).

Figure 1.

Figure 1.

Open in a new tab

Growth curve of human lung adenocarcinoma A549 cells following treatment with various concentrations of matrine. A, absorbance.

As shown in Fig. 2, matrine could effectively inhibit A549 cell proliferation. At each time point, matrine exerted inhibitory effects in a dose-dependent manner, from 60–240 mg/l. In addition, on day 3 following treatment, the inhibition reached its maximum at all concentrations except for 240 mg/l. Based on this observation, one possible explanation is that between days 3 and 4, the cells had already occupied all the culturing space and could not proliferate any further; therefore, the inhibitory rate dropped on day 4.

Figure 2.

Figure 2.

Open in a new tab

Inhibitory rate, relative to the control, of the proliferation of human lung adenocarcinoma A549 cells treated with matrine at different time points.

Matrine inhibits cell migration

As depicted in Fig. 3, A549 cell migration was reduced as the concentration of matrine was increased. Therefore, the inhibition rate of cell migration increased in a dose-dependent manner.

Figure 3.

Figure 3.

Open in a new tab

Inhibitory action of matrine on the migration of human lung adenocarcinoma A549 cells. (A) Representative images of cell migration following treatment with matrine (magnification, ×200). (B) Cells were treated with an increasing concentration of matrine (group 1, control; group 2, 60 mg/l; group 3, 120 mg/l; group 4, 180 mg/l; group 5, 240 mg/l). The number of cells migrating through were calculated and (C) the percentage of inhibition was determined relative to the control. The data are presented as the mean ± standard deviation (*P<0.05 vs. 60 mg/l).

Apoptosis is increased in cells treated with a high concentration of matrine

Based on the growth curve of A549 cells (Fig. 1), matrine at 240 mg/l exhibited the strongest inhibitory effects 48 h after treatment; therefore, 240 mg/l of matrine was chosen as the treatment condition. Even higher concentrations of matrine may lead to early cell death, thus indicating that other types of cell death may have occurred. Therefore, only 240 mg/l matrine was used to treat cells in the apoptosis assay. A549 cells were treated with 240 mg/l matrine in order to investigate its effect on the apoptotic rate compared with that of the control group. Flow cytometry indicated (Fig. 4) that the apoptotic rate in the 240 mg/l matrine-treated group was significantly higher when compared with the control group (P<0.05).

Figure 4.

Figure 4.

Open in a new tab

Matrine induces the apoptosis of A549 cells. (A) Flow cytometry revealed that apoptosis was induced following treatment with matrine. Percentage of live (lower left), early apoptotic (lower right) and late apoptotic (upper right) populations are indicated. (B) The rate of apoptosis was determined (*P<0.05 vs. control).

Matrine treatment increases the mRNA expression levels of p53 and p21, whilst reducing that of PCNA and eIF4E

The RT-qPCR findings indicated that the mRNA expression levels of p53 and p21 were significantly higher in the 240 mg/l matrine group compared with the control group (P<0.05; Fig. 5A). The mRNA expression levels of PCNA and eIF4E were significantly lower in the 240 mg/l matrine group compared with the control (P<0.05).

Figure 5.

Figure 5.

Open in a new tab

Reverse transcription-quantitative polymerase chain reaction. (A) Effect of matrine treatment on the mRNA expression levels of p53, p21, PCNA, and eIF4E (*P<0.05 vs. control). (B) Amplification and (C) melting curves. PCNA, proliferating cell nuclear antigen; eIF4E, eukaryotic translation initiation factor 4E; RFU, relative fluorescence unit.

The Cq values of the RT-qPCR amplification curves of p53, p21, PCNA and eIF4E genes (Fig. 5B) were between 20 and 40. The results indicated that the p53, p21, PCNA and eIF4E have been successfully amplified. There was a steep peak in all RT-qPCR amplification curves, indicating that only one DNA product was formed during the reaction.

Matrine treatment increases the protein expression levels of p53 and p21, whilst reducing that of PCNA and eIF4E

Western blot analysis (Fig. 6) revealed that the protein expression levels of p53 and p21 were significantly higher in the 240 mg/l matrine-treated group compared with the control group (P<0.05). The protein expression levels of PCNA and eIF4E were significantly lower in the 240 mg/l matrine-treated group compared with the control group (P<0.05).

Figure 6.

Figure 6.

Open in a new tab

Effect of matrine on the protein expression levels of p53, p21, PCNA and eIF4E (*P<0.05 vs. control). Western blotting was performed to determine the protein expression levels of certain proteins following treatment with 240 mg/l matrine. (A) The relative protein expression levels were determined. β-actin was used as a loading control. (B) Representative western blot images. PCNA, proliferating cell nuclear antigen; eIF4E, eukaryotic translation initiation factor 4E.

Discussion

Matrine (C15H24N2O) is usually derived from the legume, Sophora flavescens Ait (18), however the bioactive compound may also be extracted from other species belonging to the same genus, including Sophora subprostrata (19) and Sophora alopecuroides (20). Matrine exerts excellent pharmacological activity and is beneficial for lowering body temperature, promoting diuresis, detoxifying, treating jaundice and preventing liver fibrosis. Previous studies indicated that matrine may be used as an effective treatment for various types of cancer, including liver (21) and lung cancer (22), gastric (23) and colon cancer (24), cervical cancer (25), leukemia (26), osteosarcoma (27), glioma (28) and nasopharyngeal carcinoma (29), and exhibits potent activity against various other types of cancer. Lung cancer occurs in the bronchial epithelium (30) and is characterized by a high morbidity rate (31), a considerable degree of malignancy, a great metastatic propensity in the early stages and the tendency to recur following tumor excision (32). The present study aimed to investigate the effects of matrine on the proliferation of A549 human lung adenocarcinoma cells and on the mRNA and protein expression levels of p53, p21, PCNA and eIF4E. Additionally the current study aimed to determine the possible mechanisms by which matrine affects in order to inhibit A549 cell proliferation.

The main cell invasion and metastasis processes of A549 human lung adenocarcinoma cells and other tumor cells involves the adhesion of tumor cells to the basement membrane, which leads to the degradation of the extracellular matrix, promoting migration and invasion of cancerous cells, resulting in metastasis. Therefore, in the event that any of these stages are inhibited, the metastasis process would likely be inhibited, leading to of human lung adenocarcinoma A549 cells.

Initially, the present study used different concentrations (60, 120, 180 and 240 mg/l) of matrine as a preliminary dosage. Via growth curves, it was established that all matrine concentrations used had a slight effect on the proliferation of A549 human lung adenocarcinoma cells. However, the most marked effect was in cells treated with 240 mg/l matrine

Migration of A549 cells and other tumor cells is an important stage between the invasion and metastasis progression. Therefore, Transwell cell migration experiments were used to determine the influence of 60, 120, 180 and 240 mg/l matrine on A549 lung cancer cell migration. As matrine concentration was increased, the rate of A549 cell migration was inhibited in a dose-dependent manner.

Apoptosis is a fundamental biological phenomenon in the cell life cycle, which has been important for the evolution of organisms as it allows for the removal of unhealthy or dysfunctional cells. The present study used flow cytometry to investigate the effect of 240 mg/l matrine on the apoptosis of A549 human lung adenocarcinoma cells. The results suggested that the apoptotic rate following the application of 240 mg/l matrine was significantly higher when compared with the control group. It was concluded that a concentration of 240 mg/l matrine induced considerable levels of apoptosis in A549 cells.

The p53 gene is a tumor suppressor gene (33), which is frequently termed a ‘genetic guardian’. When DNA is damaged, the expression levels of p53 increase rapidly (34). If the p53 gene harbors a mutation, the activity of the p53 protein is reduced, leading to uncontrolled cell division and ultimately, the occurrence of cancer (35).

In recent years, p21 has been identified as an important member of the cyclin-dependent kinase inhibitor family (36), which is located downstream of the p53 gene (37). p21 and p53 contribute to the regulation of the G1 checkpoint of the cell cycle. As the damaged DNA cannot pass the G1 checkpoint without repair, the replication and the accumulation of damaged DNA can be reduced substantially. Therefore, the G1 checkpoint is important for tumor suppression (38). Previous studies (11,22) have determined that the p21 gene is associated with tumor differentiation, depth of invasion, proliferation and metastasis of tumors, and is also valuable as a prognostic sign for tumor progression.

PCNA may be used as an indicator to evaluate the state of cell proliferation (39). A close association exists between PCNA and DNA synthesis (40). PCNA is also important for the initiation of cell proliferation. Previous experimental findings indicated that the expression of PCNA is associated with the stage of lung cancer, and in the later phases of lung cancer progression, the expression of PCNA is higher (41).

eIF4E is a cap-binding protein (42), which is important for the initial process of translation in eukaryotes. It is also closely associated with tumor occurrence, infiltration and metastasis; therefore, it is highly expressed in human lung cancer and various other malignancies (43).

In the present study, RT-qPCR results indicated that the mRNA expression levels of p53 and p21 in the 240 mg/l matrine group were higher compared with the control group. Additionally, western blotting revealed that the protein expression levels of p53 and p21 in the 240 mg/l matrine group were also elevated compared with the control group. Therefore, matrine may promote the expression of p53 and p21 in A549 cells.

The RT-qPCR results also indicated that the mRNA expression levels of PCNA and eIF4E in the treatment group were lower compared with that in the control group. Furthermore, the reduction of PCNA and eIF4E expression levels following 240 mg/l matrine treatment, was less than that of the control group. Therefore, it is possible that matrine inhibits the gene expression of PCNA and eIF4E in A549 cells.

In conclusion, the findings of the present study indicated that matrine may inhibit the proliferation of A549 cells. The underlying mechanism may be associated with the induction of the expression levels of p53 and p21, and the inhibitory effect of matrine on the mRNA expression levels of PCNA and eIF4E. PCNA activity in DNA repair increases resistance to chemotherapy, and activation of p53 in response to DNA damage is correlated with a rapid increase in p53 expression level and enhanced p53 binding to DNA. This leads to the activation of various genes, including p21, and affects the phosphorylation of the eIF4E binding protein. The present study provides evidence that matrine-induced apoptosis and growth inhibition of lung cancer cells may be mediated by p53 activation, suggesting that matrine may serve as an adjuvant chemotherapeutic agent for lung cancer.

Acknowledgements

The present study was supported by the Science and Technology Department of Hubei Province (no. 20001P1804), the Natural Science Foundation of Jiangxi Province (no. 20122BAB205077) and the Natural Science Youth Foundation of Jiangxi Province (no. 20122BAB215042).

References

  • 1.Kajatt Amorin E. Lung cancer: A review of current knowledge, diagnostic methods and therapeutic perspectives. Rev Peru Med Exp Salud Publica. 2013;30:85–92. doi: 10.1590/s1726-46342013000100017. (In Spanish) [DOI] [PubMed] [Google Scholar]
  • 2.Spaans JN, Goss GD. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol. 2014;4:190. doi: 10.3389/fonc.2014.00190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lu ZG, Li MH, Wang JS, Wei DD, Liu QW, Kong LY. Developmental toxicity and neurotoxicity of two matrine-type alkaloids, matrine and sophocarpine, in zebrafish (Danio rerio) embryos/larvae. Reprod Toxicol. 2014;47:33–41. doi: 10.1016/j.reprotox.2014.05.015. [DOI] [PubMed] [Google Scholar]
  • 4.Liu YQ, Li Y, Qin J, Wang Q, She YL, Luo YL, He JX, Li JY, Xie XD. Matrine reduces proliferation of human lung cancer cells by inducing apoptosis and changing miRNA expression profiles. Asian Pac J Cancer Prev. 2014;15:2169–2177. doi: 10.7314/APJCP.2014.15.5.2169. [DOI] [PubMed] [Google Scholar]
  • 5.Yang CL, Liu SS, Ma YG, Liu YY, Xue YX, Huang B. The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis. Med Oncol. 2012;29:574–581. doi: 10.1007/s12032-011-9849-4. [DOI] [PubMed] [Google Scholar]
  • 6.Rogler CE, Chisari FV. Cellular and molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis. 1992;12:265–278. doi: 10.1055/s-2007-1007398. [DOI] [PubMed] [Google Scholar]
  • 7.Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol. 2003;82:111–120. doi: 10.1002/jso.10186. [DOI] [PubMed] [Google Scholar]
  • 8.Matsui TA, Sowa Y, Murata H, Takagi K, Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T, Sakai T. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 2007;31:915–922. [PubMed] [Google Scholar]
  • 9.Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21 (WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124:1637–1644. doi: 10.1182/blood-2014-03-559591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Yeo D, He H, Baldwin GS, Nikfarjam M. The role of p21-activated kinases in pancreatic cancer. Pancreas. 2015;44:363–369. doi: 10.1097/MPA.0000000000000276. [DOI] [PubMed] [Google Scholar]
  • 11.Xie D, Lan L, Huang K, Chen L, Xu C, Wang R, Shi Y, Wu X, Wang L, Liu Y, Lu B. Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients. Oncol Rep. 2014;32:2517–2526. doi: 10.3892/or.2014.3538. [DOI] [PubMed] [Google Scholar]
  • 12.Freund G, Desplancq D, Stoessel A, Weinsanto R, Sibler AP, Robin G, Martineau P, Didier P, Wagner J, Weiss E. Generation of an intrabody-based reagent suitable for imaging endogenous proliferating cell nuclear antigen in living cancer cells. J Mol Recognit. 2014;27:549–558. doi: 10.1002/jmr.2378. [DOI] [PubMed] [Google Scholar]
  • 13.Halvorsen OJ. Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. APMIS. 2008:5–62. Suppl. [PubMed] [Google Scholar]
  • 14.Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L, Gao Q, Shen G. Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn Schmiedebergs Arch Pharmacol. 2015;388:295–304. doi: 10.1007/s00210-014-1071-4. [DOI] [PubMed] [Google Scholar]
  • 15.Chakravarthy R, Clemens MJ, Pirianov G, Perdios N, Mudan S, Cartwright JE, Elia A. Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis. Biol Cell. 2013;105:414–429. doi: 10.1111/boc.201300021. [DOI] [PubMed] [Google Scholar]
  • 16.Martineau Y, Azar R, Müller D, Lasfargues C, El Khawand S, Anesia R, Pelletier J, Bousquet C, Pyronnet S. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene. 2014;33:1367–1374. doi: 10.1038/onc.2013.100. [DOI] [PubMed] [Google Scholar]
  • 17.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 18.Bi W, Tian M, Row KH. Solid-phase extraction of matrine and oxymatrine from Sophora flavescens Ait using amino-imidazolium polymer. J Sep Sci. 2010;33:1739–1745. doi: 10.1002/jssc.200900835. [DOI] [PubMed] [Google Scholar]
  • 19.Cho CH, Chuang CY, Chen CF. Study of the antipyretic activity of matrine. A lupin alkaloid isolated from Sophora subprostrata. Planta Med. 1986:343–345. doi: 10.1055/s-2007-969179. [DOI] [PubMed] [Google Scholar]
  • 20.Wang H, Guo S, Qian D, Qian Y, Duan JA. Comparative analysis of quinolizidine alkaloids from different parts of Sophora alopecuroides seeds by UPLC-MS/MS. J Pharm Biomed Anal. 2012;67–68:16–21. doi: 10.1016/j.jpba.2012.04.024. [DOI] [PubMed] [Google Scholar]
  • 21.Ou X, Chen Y, Cheng X, Zhang X, He Q. Potentiation of resveratrol-induced apoptosis by matrine in human hepatoma HepG2 cells. Oncol Rep. 2014;32:2803–2809. doi: 10.3892/or.2014.3512. [DOI] [PubMed] [Google Scholar]
  • 22.Niu H, Zhang Y, Wu B, Zhang Y, Jiang H, He P. Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathway. Oncol Rep. 2014;32:1087–1093. doi: 10.3892/or.2014.3273. [DOI] [PubMed] [Google Scholar]
  • 23.Li H, Xie S, Liu X, Wu H, Lin X, Gu J, Wang H, Duan Y. Matrine alters microRNA expression profiles in SGC-7901 human gastric cancer cells. Oncol Rep. 2014;32:2118–2126. doi: 10.3892/or.2014.3447. [DOI] [PubMed] [Google Scholar]
  • 24.Zhang S, Cheng B, Li H, Xu W, Zhai B, Pan S, Wang L, Liu M, Sun X. Matrine inhibits proliferation and induces apoptosis of human colon cancer LoVo cells by inactivating Akt pathway. Mol Biol Rep. 2014;41:2101–2108. doi: 10.1007/s11033-014-3059-z. [DOI] [PubMed] [Google Scholar]
  • 25.Zhang L, Wang T, Wen X, Wei Y, Peng X, Li H, Wei L. Effect of matrine on HeLa cell adhesion and migration. Eur J Pharmacol. 2007;563:69–76. doi: 10.1016/j.ejphar.2007.01.073. [DOI] [PubMed] [Google Scholar]
  • 26.Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, Wu J, Yu K, Han Y. Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One. 2012;7:e46853. doi: 10.1371/journal.pone.0046853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Li Y, Zhang ZN, Zhao HM, Tong ZC, Yang J, Wang H, Liang XJ. Matrine inhibits the invasive properties of human osteosarcoma cells by downregulating the ERK-NF-kB pathway. Anticancer Drugs. 2014;25:1035–1043. doi: 10.1097/CAD.0000000000000136. [DOI] [PubMed] [Google Scholar]
  • 28.Zhang S, Qi J, Sun L, Cheng B, Pan S, Zhou M, Sun X. Matrine induces programmed cell death and regulates expression of relevant genes based on PCR array analysis in C6 glioma cells. Mol Biol Rep. 2009;36:791–799. doi: 10.1007/s11033-008-9247-y. [DOI] [PubMed] [Google Scholar]
  • 29.Xie M, He G, Wang R, Shi S, Chen J, Ye Y, Xie L, Yi X, Tang A. Matrine-induced apoptosis of human nasopharyngeal carcinoma cells via in vitro vascular endothelial growth factor-A/extracellular signal-regulated kinase1/2 pathway inactivation. Horm Metab Res. 2014;46:556–560. doi: 10.1055/s-0034-1367077. [DOI] [PubMed] [Google Scholar]
  • 30.Keith RL. Chemoprevention of lung cancer. Proc Am Thorac Soc. 2009;6:187–193. doi: 10.1513/pats.200807-067LC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Saika K, Sobue T. Lung cancer: Progress in diagnosis and treatments. Topics I. Epidemiology and pathogenesis; 1. Epidemiology, prevention and screening. Nihon Naika Gakkai Zasshi. 2014;103:1255–1260. doi: 10.2169/naika.103.1255. (In Japanese) [DOI] [PubMed] [Google Scholar]
  • 32.Nykainen A, Räsänen J, Salo J, Sihvo E. Thoracoscopic surgery of lung cancer. Duodecim. 2014;130:145–151. (In Finnish) [PubMed] [Google Scholar]
  • 33.Pflaum J, Schlosser S, Müller M. p53 family and cellular stress responses in cancer. Front Oncol. 2014;4:285. doi: 10.3389/fonc.2014.00285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010;396:85–89. doi: 10.1016/j.bbrc.2010.02.152. [DOI] [PubMed] [Google Scholar]
  • 35.Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 2001;277:15–30. doi: 10.1016/S0378-1119(01)00696-5. [DOI] [PubMed] [Google Scholar]
  • 36.Marone M, Bonanno G, Rutella S, Leone G, Scambia G, Pierelli L. Survival and cell cycle control in early hematopoiesis: Role of bcl-2 and the cyclin dependent kinase inhibitors P27 and P21. Leuk Lymphoma. 2002;43:51–57. doi: 10.1080/10428190210195. [DOI] [PubMed] [Google Scholar]
  • 37.Saegusa M, Hashimura M, Suzuki E, Yoshida T, Kuwata T. Transcriptional up-regulation of Sox9 by NF-kB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14 (ARF)/p53/p21 (WAF1) pathway. Am J Pathol. 2012;181:684–692. doi: 10.1016/j.ajpath.2012.05.008. [DOI] [PubMed] [Google Scholar]
  • 38.Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, Ward AJ, Raj A, Lee JT, Sharp PA, Jacks T. LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell. 2014;54:777–790. doi: 10.1016/j.molcel.2014.04.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Chen W, Yoshida S, Ohara N, Matsuo H, Morizane M, Maruo T. Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly (adenosine 5′-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells. J Clin Endocrinol Metab. 2005;90:884–892. doi: 10.1210/jc.2004-1591. [DOI] [PubMed] [Google Scholar]
  • 40.Gao X, Dan S, Xie Y, Qin H, Tang D, Liu X, He QY, Liu L. 14-3-3ζ reduces DNA damage by interacting with and stabilizing proliferating cell nuclear antigen. J Cell Biochem. 2015;116:158–169. doi: 10.1002/jcb.24955. [DOI] [PubMed] [Google Scholar]
  • 41.Oyama T, Mitsudomi T, Mizoue T, Ohgami A, Osaki T, Nakanishi R, Yasumoto K. Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol. 1995;4:83–89. doi: 10.1016/S0960-7404(10)80011-8. [DOI] [PubMed] [Google Scholar]
  • 42.Sonenberg N. eIF4E, the mRNA cap-binding protein: From basic discovery to translational research. Biochem Cell Biol. 2008;86:178–183. doi: 10.1139/O08-034. [DOI] [PubMed] [Google Scholar]
  • 43.Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13:272–280. doi: 10.4161/cbt.18923. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Medicine Reports are provided here courtesy of Spandidos Publications

RESOURCES